Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE study of AR101 for peanut allergy desensitization
NL-OMON47055Phase 3Active, not recruiting
- Sponsor
- Aimmune Therapeutics
- Start
- Jun 2016
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of peanut protein, sponsored by Aimmune Therapeutics. Started Jun 2016; status: active, not recruiting.
02
Drugs
peanut protein
Beyond the preview
Go deeper on NL-OMON47055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47055.